Autres langues Repligen Corporation

Actions

RGEN

US7599161095

Equipement, fournitures et distribution médicale

Marché Fermé - Nasdaq 22:00:00 25/08/2026			Varia. 5j.	Varia. 1 janv.
181,69 ^USD	+0,04%		+7,48%	+10,88%

24/08	Les plus fortes baisses à la mi-séance	MT
24/08	Azenta nomme Martin Madaus, membre du conseil d'administration, au poste de PDG par intérim	MT

Autres langues

24/08	Top Midday Decliners
24/08	Azenta Names Board Member Martin Madaus as Interim CEO
29/07	Tranche Update on Repligen Corporation's Equity Buyback Plan announced on June 18, 2008.
29/07	Tranche Update on Repligen Corporation's Equity Buyback Plan announced on December 7, 2023.
29/07	Repligen's Diversity of Growth Drivers Support Return to Mid-Teens Organic Sales Growth, RBC Says
28/07	Repligen Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
28/07	Repligen's Q2 Adjusted Earnings, Revenue Increase; 2026 Outlook Raised
28/07	(RGEN) Repligen Expects 2026 Adjusted EPS Range $2.03-$2.09, vs. FactSet Est of $2.00
28/07	Earnings Flash (RGEN) Repligen Corporation Reports Q2 Revenue $204.1M, vs. FactSet Est of $201.6M
28/07	Earnings Flash (RGEN) Repligen Corporation Posts Q2 Adjusted EPS $0.54 per Share, vs. FactSet Est of $0.45
28/07	Repligen: Q2 Earnings Snapshot
28/07	Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
22/07	Top Midday Stories: Trump Threatens Retaliation for Attacks in Strait of Hormuz; AMD to Supply MI450 GPUs to Anthropic
22/07	Repligen Corporation entered into an agreement and plan of merger to acquire BioLife Solutions, Inc. for approximately $1.6 billion.
22/07	Repligen beefs up cell therapy business with $1.5 billion deal for BioLife
22/07	Repligen to Acquire BioLife Solutions in $1.5 Billion Cash-and-Stock Deal
22/07	Repligen to Acquire BioLife Solutions in $1.5 Billion Cash-and-Stock Deal
22/07	Repligen to buy BioLife Solutions in $1.5 billion deal
22/07	Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media
21/07	Deals of the day-Mergers and acquisitions
15/07	Repligen to Report Second Quarter 2026 Financial Results
29/06	Repligen Corporation(NasdaqGS:RGEN) dropped from Russell Small Cap Comp Growth Benchmark
29/06	Repligen Corporation(NasdaqGS:RGEN) dropped from Russell 2500 Growth Benchmark
29/06	Repligen Corporation(NasdaqGS:RGEN) dropped from Russell Midcap Growth Benchmark
29/06	Repligen Corporation(NasdaqGS:RGEN) dropped from Russell 3000E Growth Benchmark